Clinical trial
AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy
NCT04597411 is registered in ClinicalTrials.gov with Endocyte as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy
- Lead sponsor
- Endocyte
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- April 1, 2021
- Completion date
- January 1, 2027
- Enrollment
- 101 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.